13 February – LAWFUEL – The Law News Network – Allen & Overy advised international biotechnology company, Crucell N.V., headquartered in the Netherlands, on its SFR 590 million all-share offer for the shares of Swiss vaccines company Berna Biotech AG.
Under the terms of the offer, Crucell will issue up to a maximum of 18,000,000 ordinary shares to the shareholders of Berna. As a result, Crucell and Berna’s current shareholders will own approximately 73% and 27%, respectively, of Crucell.
The Allen & Overy team was led by Johan Kleyn, together with Robert Jan Lijdsman and Tim Stevens, assisted by associates Bondine Brons, Jetty Tukker and Lucas Brabers.
Commenting, Johan Kleyn said: “This was a very exciting cross-border transaction, in which we acted as international counsel for our longstanding client, Crucell. We are delighted with the outstanding result accomplished by Crucell.”
For further information, please contact Rhimou Bensalah (rhimou.bensalah@allenovery.com) on +31 20 674 1307 or Jo Shepherd (jo.shepherd@allenovery.com) on +44 (0) 20 7330 2195.
